Navigation Links
When Prescribing New Drugs for Crohn's Disease or Ulcerative Colitis, Surveyed EU5 Gastroenterologists Will Prioritize Remission Rates Over Cost and Reimbursement Hurdles
Date:12/16/2013

BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, when considering the most important attributes for prescribing emerging therapies for Crohn's disease (CD) and ulcerative colitis (UC), instead of using leading anti-TNF agents (Merck's Remicade and AbbVie's Humira), 44 to 70 percent of surveyed gastroenterologists cite higher rates of induction and maintenance of remission as the primary driver. In addition, 12 to 34 percent of surveyed gastroenterologists identify superior efficacy over anti-TNFs in head-to-head trials as another driver, while only up to 10 percent of physicians list the nonclinical factors, lower cost burden and fewer reimbursement restrictions.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

Lack of initial efficacy and waning efficacy over time are also the primary reasons currently driving discontinuation of the anti-TNF-alpha agents, according to survey respondents. While the emerging biologics vedolizumab (Takeda) for CD and UC and Stelara (Janssen) for CD show at least comparable efficacy at maintenance of remission when indirectly compared to Remicade, in the absence of head-to-head comparative data that show superiority over this agent or other anti-TNFs, vedolizumab and Stelarawill face challenges in gaining preferential uptake.

The European Physician & Payer Forum report entitled Crohn's Disease and Ulcerative Colitis in the EU5: How Will Pricing and Reimbursement Decisions for Novel Biologics and Oral Immunomodulators Impact Prescribing? also emphasizes the importance of direct comparative data for favorable pricing and reimbursement of emerging biologics. As more rigorous health technology assessments that focus on added benefit are introduced across the EU5, proven superiority over appropriate comparators is increasingly required for optimal pricing and reimbursement. For example, based on indirect comparison with Remicade, interviewed payers believe that the clinical profile of vedolizumab in CD or UC is not strong enough to justify reimbursement before anti-TNFs if priced at a 25 percent or greater premium.

"While EU5 gastroenterologists expect vedolizumab to encroach on their use of anti-TNFs by the end of 2017, in the absence of a head-to-head trial showing evidence of superior efficacy that may justify use before anti-TNFs and with a potentially higher price, anti-TNFs will continue to dominate patient share," said Decision Resources Analyst Kathrina Quinn, Ph.D. "These data also reflect the expected entry of the more favorably priced biosimilar infliximab, which will bolster drug class share. At least 74 percent of surveyed gastroenterologists expect to prescribe biosimilar versions of Remicade within a year of availability for either CD or UC, but many are willing to do so under certain conditions only, such as if an acceptable safety and/or immunogenicity profile is shown."  

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nations Largest Medical Society Says Doctors Should Check Drug Database Before Prescribing Addictive Drugs, Says Consumer Watchdog Campaign
2. New Study Evaluates Psychotropic Prescribing For Persons with Intellectual Disabilities, Other Psychiatric Disorders
3. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
4. U.S. Physician Prescribing Behavior Impacted by Health Insurance Exchanges and Accountable Care Organizations
5. Lack of Formulary Access Tops List of Limitations Primary Care Physicians Face With e-Prescribing Systems, Says New Research Report from SciMedica Group MR&C
6. Paul Kauffman of Accident Fund to Present on Identifying Risky Opioid Prescribing Patterns at 99th Annual International Association of Industrial Accident Boards & Commissions Conference
7. Differences Over Pathways Developed by Oncologists and MCOs May Create Conflict Over Prescribing Decisions in Early-Line Treatment
8. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
9. U.S. and European Rheumatologists Agree That a Therapys Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis
10. Approval for One Neuropathic Pain Indication is Sufficient to Support Physician Prescribing and Payer Reimbursement Across Multiple Neuropathic Pain Populations
11. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
(Date:1/19/2017)... 19, 2017 ViewRay, Inc. (Nasdaq: VRAY) announced today ... supporting research in Germany , has ... at the University Clinic Heidelberg as part of its ... Linac program will be headed by Medical Director and ... oncology at the German Cancer Research Center (DKFZ), the ...
(Date:1/19/2017)... , January 19, 2017 ... administration appears serious about reducing the FDA,s regulatory ... innovation in the medical drug industry, many of ... with new clinical trials and development of advanced ... forging ahead with recent developments include:  Moleculin Biotech, ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Creative messages to prevent distracted driving ... Impact Teen Drivers and California Casualty. Entries from students aged 14-22 can be ... $15,000 will be awarded for the best peer-to-peer messages sharing solutions to reckless ...
(Date:1/19/2017)... ... January 18, 2017 , ... The CHP suggests that California drivers can avoid ... slowing down and increasing the space between themselves and other vehicles, according to a ... attorney Raymond R. Hassanlou notes that, rain or shine, drivers should always incorporate safe ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Connecticut Dermatology Group ... Kim, a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive background ... , “It is with considerable pleasure to welcome back Dr. Kim to the CDG ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), a ... the US market. , Over the past 20 years SFI has been recognized as ... has launched six new clients into the US market. The new clients include: ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced today that Dan ... sales and marketing strategies. Grover comes with a total of 15 years experience in ... years as Executive Vice President of Direct Sales at Traeger® Wood Pellet Grills. ...
Breaking Medicine News(10 mins):